Endurant Capital Management’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-79,471
Closed -$2.01M 40
2023
Q3
$2.01M Hold
79,471
1.8% 19
2023
Q2
$1.68M Sell
79,471
-150,535
-65% -$2.86M 1.46% 20
2023
Q1
$3.92M Sell
230,006
-13,116
-5% -$255K 2.01% 15
2022
Q4
$4.86M Buy
243,122
+135,409
+126% +$2.62M 1.97% 13
2022
Q3
$2.32M Sell
107,713
-34,358
-24% -$824K 0.76% 30
2022
Q2
$2.8M Sell
142,071
-23,209
-14% -$486K 0.98% 27
2022
Q1
$3.88M Buy
165,280
+76,069
+85% +$1.77M 1.02% 28
2021
Q4
$2.43M Sell
89,211
-70,692
-44% -$2.02M 0.59% 36
2021
Q3
$4.4M Sell
159,903
-100,411
-39% -$2.63M 1% 27
2021
Q2
$7.41M Buy
260,314
+127,892
+97% +$3.8M 2.04% 17
2021
Q1
$4.51M Buy
132,422
+8,099
+7% +$310K 1.18% 34
2020
Q4
$4.14M Sell
124,323
-19,990
-14% -$730K 1.49% 26
2020
Q3
$4.64M Buy
144,313
+4,129
+3% +$119K 1.37% 24
2020
Q2
$3.86M Buy
140,184
+65,819
+89% +$1.56M 0.21% 27
2020
Q1
$1.19M Buy
+74,365
New +$1.76M 0.54% 35
2018
Q1
Sell
-22,910
Closed -$714K 79
2017
Q4
$714K Sell
22,910
-72,490
-76% -$2.14M 0.22% 64
2017
Q3
$2.98M Buy
+95,400
New +$1.82M 0.9% 40

Other funds holding INSM

Endurant Capital Management's INSM Position: Q4 2023 in Review

Endurant Capital Management sold out of Insmed (INSM) in Q4 2023, closing a stake of 79,471 shares — an estimated $2.01M sold.

Endurant Capital Management first reported a position in INSM in Q3 2017 and held it in 17 quarters. The position peaked at $7.41M in Q2 2021. 271 funds tracked by Wall St. Rank hold INSM as of Q4 2023.

  • Endurant Capital Management reported no remaining Insmed position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 79,471 Insmed shares in Q4 2023, an estimated $2.01M.
  • Endurant Capital Management first reported a position in Insmed in Q3 2017 and held it in 17 quarters.
  • Endurant Capital Management's Insmed position peaked at $7.41M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held Insmed as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.